Q4 2022 EPS Estimates for Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Lifted by HC Wainwright

Freeline Therapeutics Holdings plc (NASDAQ:FRLNGet Rating) – Stock analysts at HC Wainwright raised their Q4 2022 earnings per share (EPS) estimates for Freeline Therapeutics in a research report issued to clients and investors on Tuesday, November 22nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.21) for the quarter, up from their previous forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Freeline Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Freeline Therapeutics’ Q1 2023 earnings at ($0.21) EPS, Q2 2023 earnings at ($0.13) EPS, Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.10) EPS, FY2023 earnings at ($0.48) EPS and FY2024 earnings at ($0.31) EPS.

Separately, BTIG Research reduced their price objective on Freeline Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, August 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Freeline Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Freeline Therapeutics Price Performance

Shares of NASDAQ:FRLN opened at $0.64 on Thursday. Freeline Therapeutics has a 52-week low of $0.60 and a 52-week high of $2.75. The stock has a market cap of $41.57 million, a price-to-earnings ratio of -0.30 and a beta of 0.20. The business has a 50-day moving average price of $0.71 and a 200-day moving average price of $0.80.

Institutional Trading of Freeline Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Syncona Portfolio Ltd grew its holdings in Freeline Therapeutics by 645.7% during the first quarter. Syncona Portfolio Ltd now owns 21,997,620 shares of the company’s stock worth $5,841,000 after acquiring an additional 19,047,620 shares during the period. TFG Asset Management GP Ltd grew its holdings in Freeline Therapeutics by 6.4% during the third quarter. TFG Asset Management GP Ltd now owns 4,000,000 shares of the company’s stock worth $2,800,000 after acquiring an additional 239,492 shares during the period. Eventide Asset Management LLC grew its holdings in Freeline Therapeutics by 3.5% during the first quarter. Eventide Asset Management LLC now owns 3,606,192 shares of the company’s stock worth $3,970,000 after acquiring an additional 120,536 shares during the period. UBS Group AG acquired a new stake in Freeline Therapeutics during the first quarter worth about $565,000. Finally, Renaissance Technologies LLC grew its holdings in Freeline Therapeutics by 112.5% during the first quarter. Renaissance Technologies LLC now owns 446,412 shares of the company’s stock worth $500,000 after acquiring an additional 236,312 shares during the period. 58.48% of the stock is owned by institutional investors and hedge funds.

About Freeline Therapeutics

(Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Recommended Stories

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.